GLPwatch
Study to Evaluate Safety and PK/PD of DA-3091 in Healthy Male Subjects
NCT01156779 · Completed
Last updated 2026-05-28This clinical trial tests the safety and how the body processes DA-3091 in healthy adult men.
Status Completed The study has finished.
Phase Phase 1 Checks safety and dosing in a small group.
Type Interventional (clinical trial)
Design Randomized, quadruple-blind treatment study
Participants 31 people
Who can join Ages 20–45 · male only Healthy volunteers accepted.
Timeline Started 2010-07
Where 1 site · South Korea
What this study is testing ClinicalTrials.gov NCT01156779 ↗
Description as written by the study sponsor.
This Phase I clinical study is to evaluate the safety and tolerance of DA-3091 and to characterize the pharmacokinetic/pharmacodynamic of DA-3091 in healthy male subjects
Treatments tested
- SR-exenatide also known as DA-3091 Drug
Emulsion 0.5mg,1mg,2mg,4mg dosage (Dose-escalation) Single injection
| Main thing measured | Assessment of safety |
|---|---|
| Sponsor | Dong-A Pharmaceutical Co., Ltd. |
| Conditions studied | Diabetes Mellitus |
| GLP-1 drugs | — |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01156779 ↗